LivaNova (NASDAQ:LIVN) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

LivaNova (NASDAQ:LIVN) had its target price hoisted by research analysts at Needham & Company LLC from $64.00 to $81.00 in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 14.08% from the stock’s previous close.

A number of other research analysts have also recently commented on the company. Mizuho increased their target price on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Robert W. Baird set a $75.00 price objective on LivaNova in a research report on Tuesday, December 16th. KeyCorp began coverage on LivaNova in a research report on Friday, December 19th. They issued an “overweight” rating and a $81.00 target price for the company. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Finally, Piper Sandler restated an “overweight” rating and issued a $85.00 price objective on shares of LivaNova in a report on Thursday, February 19th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $74.11.

LivaNova Stock Up 1.0%

LIVN stock opened at $71.00 on Wednesday. The company has a current ratio of 1.36, a quick ratio of 1.12 and a debt-to-equity ratio of 0.29. The company’s 50 day moving average is $64.59 and its 200 day moving average is $58.90. The stock has a market cap of $3.88 billion, a price-to-earnings ratio of -15.92 and a beta of 0.97. LivaNova has a 1-year low of $32.48 and a 1-year high of $71.92.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. The business had revenue of $360.86 million during the quarter, compared to analysts’ expectations of $354.31 million. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The business’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Sell-side analysts predict that LivaNova will post 2.85 EPS for the current fiscal year.

Institutional Investors Weigh In On LivaNova

A number of large investors have recently modified their holdings of LIVN. Pacer Advisors Inc. raised its stake in LivaNova by 131.7% in the fourth quarter. Pacer Advisors Inc. now owns 16,661 shares of the company’s stock worth $1,025,000 after buying an additional 9,471 shares in the last quarter. Invesco Ltd. grew its holdings in shares of LivaNova by 4.5% during the 4th quarter. Invesco Ltd. now owns 1,091,086 shares of the company’s stock worth $67,135,000 after acquiring an additional 47,323 shares during the period. Corient Private Wealth LLC bought a new position in shares of LivaNova in the 4th quarter worth approximately $604,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of LivaNova in the 4th quarter valued at approximately $306,000. Finally, State of Tennessee Department of Treasury lifted its stake in shares of LivaNova by 44.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 30,304 shares of the company’s stock valued at $1,991,000 after purchasing an additional 9,396 shares during the period. Institutional investors own 97.64% of the company’s stock.

LivaNova News Summary

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q4 beat — LivaNova reported Q4 revenue of $360.9M (up ~12% YoY) and adjusted EPS of $0.86, topping consensus on both top and bottom lines; management highlighted organic growth across core businesses. LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
• Positive Sentiment: Raised FY2026 EPS guidance — management issued EPS guidance of $4.15–$4.25 versus consensus near $3.90, signaling stronger-than-expected margin and earnings leverage for the year. Revenue guidance was roughly in line with consensus (~$1.5B). LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
• Positive Sentiment: Analyst upgrade/price-target lift — Needham raised its price target to $81 and kept a Buy rating, providing additional analyst support for the rally. Livanova (LIVN) PT Raised to $81 at Needham
• Positive Sentiment: Short interest fell materially in February (down ~16.6%), lowering potential short-squeeze risk and reducing bearish positioning. (Data released by exchanges; summary in earnings coverage.)
• Neutral Sentiment: New data partnership — LivaNova announced a data partnership with Orrum that could enhance its cardiac-care analytics and reimbursement narrative, but the commercial impact is still speculative. Could LivaNova’s (LIVN) Data Partnership With Orrum Quietly Reshape Its Cardiac Care Narrative?
• Neutral Sentiment: Earnings materials and call transcript released — slide deck and full call transcript are available for investors to review execution details and product cadence. LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Margin profile and GAAP metrics — despite adjusted EPS beats, LivaNova still shows pressure on GAAP margins (company-reported net margin metrics), which investors will watch as guidance is executed. LivaNova Q4 Earnings Snapshot

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.